N/A
Completed N=16
Acute Effects of Coffee on Appetite and Inflammation Markers, Glucose Metabolism and Energy Intake
Health
Source: ClinicalTrials.gov NCT01174576 ↗
Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Sep 2013
Primary outcomePrimary: Ghrelin Total Area Under the Curve — 2669; 2593; 2672 ug*h/mL
Summary
The purpose of the study is to investigate whether caffeinated and decaffeinated coffee consumption has acute effects on subjective appetite feelings, energy intake and biochemical markers related to appetite, inflammation and glucose metabolism compared to water consumption.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Ghrelin Total Area Under the Curve |
2669; 2593; 2672 | — |
| PRIMARY Peptide Tyrosine Tyrosine (PYY) Total Area Under the Curve |
251; 286; 259 | — |
| PRIMARY Glucagon-like Peptide-1 (GLP-1) Total Area Under the Curve |
43; 45; 61 | — |
| PRIMARY Adiponectin Total Area Under the Curve |
22.7; 22.6; 22.6 | — |
| PRIMARY Inteleukin-6 Total Area Under the Curve |
5.4; 5.5; 6.0 | — |
| PRIMARY Interleukin-18 Total Area Under the Curve |
818; 777; 786 | — |
| PRIMARY Glucose Total Area Under the Curve |
336; 329; 323 | — |
| PRIMARY Insulin Total Area Under the Curve |
54; 52; 52 | — |
| PRIMARY Cortisol Total Area Under the Curve |
43.2; 39.8; 35.0 | — |
| PRIMARY Energy ad Libitum Meal |
1749; 1720; 1750 | — |
| PRIMARY Total Energy Intake |
3223; 3445; 3302 | — |
| SECONDARY Serum Antioxidant Capacity Total Area Under the Curve |
102; 104; 108 | — |
Eligibility Criteria
Inclusion Criteria
- healthy
- non-obese
Exclusion Criteria
- smokers
- restrained eaters (as this was evaluated using the Dutch Eating Behaviour Questionnaire and a total score > 2.5)
- those who reported slimming or any other dietary regime
- abstainers from caffeine sources
- athletes during competition period
- participants with a known diagnosis of either hypertension, diabetes, impaired glucose tolerance or a fasting blood glucose concentration above 125 mg/dl
- subjects on medication for hypertension or on medication known to alter glucose metabolism
- subjects who were on medication that may have an impact on appetite and sensory functioning or who reported a metabolic or endocrine disease, gastrointestinal disorders, or a history of medical or surgical events that may have affected the study outcomes
Data sourced from ClinicalTrials.gov (NCT01174576). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.